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Background: Congenital heart defects (CHD) is the most common cause of death from a congenital structure
abnormality in newborns and is often associated with fetal loss. There are many types of CHD. Human genetic
studies have identified genes that are responsible for the inheritance of a particular type of CHD and for some
types of CHD previously thought to be sporadic. However, occasionally different members of the same family
might have anatomically distinct defects — for instance, one member with atrial septal defect, one with tetralogy
of Fallot, and one with ventricular septal defect. Our objective is to identify susceptibility loci for CHD in families
affected by distinct defects. The occurrence of these apparently discordant clinical phenotypes within one family
might hint at a genetic framework common to most types of CHD.
Results: We performed a genome-wide linkage analysis using MOD score analysis in families with diverse CHD.
Significant linkage was obtained in two regions, at chromosome 15 (15q26.3, Pempirical = 0.0004) and at
chromosome 18 (18q21.2, Pempirical = 0.0005).
Conclusions: In these two novel regions four candidate genes are located: SELS, SNRPA1, and PCSK6 on 15q26.3,
and TCF4 on 18q21.2. The new loci reported here have not previously been described in connection with CHD.
Although further studies in other cohorts are needed to confirm these findings, the results presented here together
with recent insight into how the heart normally develops will improve the understanding of CHD.
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Congenital heart defects (CHD) refer to abnormalities in
the heart structure or function that arise at the fetal
stages and affect approximately 1% of newborns [1].
Multiple surgeries are almost always required to correct
many of the anatomical defects, and quality of life is
often greatly compromised. There are many types of
CHD. Examples include transposition of the great ar-
teries/vessels (TGA/TGV), tetralogy of Fallot (TOF),
double outlet right ventricle (DORV), atrial septal de-* Correspondence: antonia.flaquer@lmu.de
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reproduction in any medium, provided the orfects (ASD), ventricular septal defects (VSD), bicuspid
aortic valve (BAV), and Ebstein’s anomaly, among many
others.
Normal heart development involves many regula-
tory pathways including receptor-ligand interactions
(JAGGED/NOTCH, TGFB-BMP/TGFBR, VEGF/FLT1-
FLK1, NODAL/ACVRA-ACVRB and RTK/RAS), signal
transduction (kinases or phosphatases such as MAPK,
ERK1/2, calcineurin, or GSK), and transcription factors
that determine the expression of cardio-specific genes
(protein families with a T-box domain TBX1, TBX5, and
TBX20, the GATA family GATA4 and FOG2 or homeobox
domain NKX2.5 and NKX2.6). Mutations that show a
greater penetrance and that therefore approximate aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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factors or genes transcribed by them [2].
Although the major underlying defects that cause
CHD are thought to be mutations in regulators of heart
development during embryogenesis, epidemiological data
also indicate an environmental influence [2-4]. However,
these epidemiological studies mostly suggest risk factors
rather than underlying disease mechanisms. Genetic fac-
tors for some of the CHD include Mendelian mutations,
copy number variants, translocations, and single nucleo-
tide polymorphisms (SNPs) [5-7].
A genetic component of CHD diseases was initially im-
plicated by recurrence in families, and by studies showing
a co-segregation of CHD with the deletion 22q11.2 [8]. It
has also been shown that individuals with an affected pa-
rent are at twofold greater risk, which is even greater if
siblings are affected [9]. While many studies have investi-
gated the role of genes in the etiology of inherited and
sporadic CHD [10-14] these studies have been focusing
on specific cardiac lesions separately. Recently, rare vari-
ants have also been reported to be associated with CHD
[15]. These rare variants are usually present in less than
1% of the normal population but are overrepresented in
selected patients. They are typically inherited from an
asymptomatic parent and are therefore not believed to be
a sufficient cause of CHD in these patients; other muta-
tions need to be present to lead to CHD.
However, occasionally, different members of one family
are observed to suffer from anatomically distinct defects —
for example, one member with ASD, one with TOF, and
one with VSD. These apparently discordant clinical phe-
notypes arising within one family are difficult to ratio-
nalize. Benson et al. [16] observed a coinheritance of
different NKX2.5 mutations, i.e., compound heterozygotes,
in members of families with ASD, VSD, and cardiac con-
duction abnormalities, suggesting that mutations in the
same gene can affect different parts of the heart, and
therefore cause different types of CHD. McGregor et al.
[17] reported a statistically significant linkage evidence for
a locus on chromosome 14 (within the HOMEZ gene) in
South Indian cases born to consanguineous parents. How-
ever, the linkage finding was not robust in a genetic
association follow-up study in a general United States
population. Despite the successes over the past few years,
much remains unknown about the genetics of CHD. It is
believed that much of the missing heritability is likely to
be due to rare variants with larger effect sizes as well as
epigenetic effects. Their systematic characterization is be-
yond the means of studies that currently rely on linkage
disequilibrium (LD) patterns such as genome-wide associ-
ation analysis. In such situations taking family information
into consideration using a direct mapping approach
complemented by segregation techniques will be a useful
strategy. For complex diseases linkage analysis is a power-ful method for detecting gene effects [18,19]. Especially
when looking at rare variants, linkage has the advantage
over association of not being prone to allelic heteroge-
neity. That is, the combination of many weak association
signals obtained in a certain region for single variants by
means of collapsing methods is automatically performed
in the context of linkage analysis.
In this study we performed a detailed genome-wide lin-
kage analysis using MOD scores and 6 families affected by
different CHD to test for a common genetic background
among different types of heart defects.
Results and discussion
The genome-wide results for MOD scores are plotted in
Figure 1. No significant results were obtained when mo-
deling parent-specific heterozygote penetrances, resulting
in no evidence of parental genomic imprinting in our set
of pedigrees. The best results were obtained on chromo-
some 15 and 18. The results for these two chromosomes
are plotted in Figures 1A and 1B, respectively. The highest
scores (MOD= 3.9) were detected on chromosome 18
(18q21.2-18q21.3; 51197–52023 kb) comprising 57 SNPs
with Pempirical = (0.0005-0.0006), where Pempirical refers to
the P value obtained after simulations were performed.
The associated parametric model is a recessive mode of
inheritance with incomplete penetrance with a probability
of 0.27 to be affected for individuals carrying two copies
of the disease allele. Incomplete penetrance refers to the
failure of individuals who carry the high risk genotype to
exhibit the trait. This phenomenon is often observed in
complex diseases. Besides different ways of gene action or
degrees of expression, incomplete penetrance can arise
from further genetic or environmental factors. The second
significant region was at chromosome 15 (15q26.3;
99749–99883 kb) comprising 27 SNPs, all of them with a
MOD score of 3.5 and Pempirical = (0.0004-0.0005). The
best-fitting model points to a recessive mode of inheri-
tance, with a probability of 0.98 to be affected for indivi-
duals carrying two copies of the disease allele. It should be
noted that the estimate of the disease allele frequency
obtained by a MOD-score analysis has the largest variance
of all trait-model parameters. Furthermore, in some cases,
the estimated disease allele frequency will be markedly
higher than the true value. This is due to the fact that spe-
cifying a higher disease allele frequency can compensate
for a general model misspecification and hence lead to
robustness in a multipoint analysis [20].
To corroborate these findings, family-based association
analysis was performed in these two significant regions
with SNPs displaying a MOD >2.5 (P value ≤ 0.01). Using
this criterion a total number of 304 SNPs (P values bet-
ween 5 × 10-04 and 1 × 10-02) and 211 SNPs (P values bet-
ween 4 × 10-04 and 4 × 10-03) were included in the
association analysis for 18q21.2-18q21.3 and 15q26.3,
− ( ) − ( )
Figure 1 Genome-wide results for the MOD score analyses. XY1 and XY2 represent pseudoautosomal regions 1 and 2, respectively.
Figures 1A and 1B illustrate the MOD score results on chromosome 15 and chromosome 18, respectively. In addition, the –log10(P value) of the
family-based association test in regions with significant MOD scores are shown as red dots.
Table 1 Parametric LOD scores for each family separately
Family Heart defect Chr15 Chr18
15q26.3 18q21.2-18q21.3
1 VSD 0.615 0.632
2 TOF,TGV 0.324 0.299
3 TOF 0.545 0.602
4 ASD 1.670 1.297
5 VSD,DORV −0.307 0.602
6 ASD 0.681 0.496
All VSD,TOF,TGV,ASD,DORV 3.529 3.929
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nificant at a type I error rate of 0.05 on chromosome 18.
Nevertheless, none of them was significant after using the
Bonferroni correction to adjust for multiple testing. On
the other hand, on chromosome 15 a total number of 39
SNPs were found to be nominally significant and only one
(rs3784481 at 99749 kb) was significant after Bonferroni
correction (P value = 0.0025).
To see if one of the two linkage regions may be the
causal genetic factor for a particular family we
performed parametric linkage (LOD score) analysis of
individual pedigrees under the best fitted model for the
two linked regions. As shown in Table 1, all the pedi-
grees contribute positively to the LOD score in both re-
gions (except pedigree 5, chr15). These positive
contributions indicate that all types of CHD present in
our pedigrees are linked to both regions, supporting the
initial hypothesis of this study of a common genetic
background for diverse CHD. The negative contribution
of pedigree 5 to the LOD score on chromosome 15 has
to be treated carefully. Due to the small number of mei-
oses in this pedigree there is a lack of power to detect
linkage, and no conclusion should be drawn when ana-
lyzing this pedigree individually.
When looking in detail at the region around the sig-
nificant SNPs on chromosome 15, three genes are foundvery closely to each other (SELS, SNRPA1, and PCSK6).
In addition, one gene is located in the linkage region
identified on chromosome 18 (TCF4).
One gene at 18q21.2: TCF4
The potentially relevant TCF4 gene is located at the
linkage peak of chromosome 18. This gene encodes tran-
scription factor 4, a basic helix-loop-helix transcription
factor. To date, no connection between this gene and
CHD has been established. However, it is interesting to
note that fairly recently it has been found that in mice
the tcf4 gene is strongly expressed in connective tissue
fibroblast. It was demonstrated that connective tissue
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myogenesis: muscle fiber type development and matur-
ation [21]. Taken together this finding in mice and our
results could suggest that malfunction of the TCF4 gene
may produce a malformation of the heart muscle tissue
which in turn predisposes to a higher risk to develop
some type of CHD.
Three genes at 15q26.3: SELS, SNRPA1, and PCSK6
The SELS gene encodes a selenoprotein, which contains
a selenocysteine residue at its active site. Studies suggest
that this protein may regulate cytokine production, and
thus play a key role in the control of the inflammatory
response decreasing pro-inflammatory cytokines [22].
Production of cytokines is one of the major mechanisms
employed by T-cells to coordinate immune responses. It
has been demonstrated that the developing immune sys-
tem of the neonate not only differs significantly from
that of an adult, but also varies based on gestational age
[23]. A malfunction of the SELS gene might provoke de-
ficient cytokine production by neonatal lymphocytes,
and somehow predispose the newborn to a higher risk
to develop some CHD. It was also shown that SELS is
secreted from hepatoma cells and that it associates with
low-density lipoprotein particles [24] suggesting also a
role in lipid metabolism. Lundell et al. [25] had already
shown in their study that lipid metabolism was disturbed
in infants with CHD. Furthermore, genetic studies in
relation to cardiovascular disease have revealed that vari-
ation in the SELS locus is associated with coronary heart
disease and ischemic stroke in women [26].
The SNRPA1 gene encodes the U2 small ribonucleopro-
tein A’ (U2 snRNP A’). The action of snRNPs is essential
to the removal of introns from pre-mRNA, a critical as-
pect of post-transcriptional modification of RNA. To date
no association has been reported between SNRPA1 and
heart defects. However, post-transcriptional modification
is one of the multiple mechanisms that regulate the level
and activity of transcription factors which are responsible
for regulating formation and function of the heart. Pertur-
bations of transcription factor expression and regulation
disrupt normal heart structure and function [27].
The protein encoded by the PCSK6 gene belongs to the
subtilisin-like proproteinconvertase family. The members
of this family are proproteinconvertases that process latent
precursor proteins into their biologically active products.
This encoded protein is a calcium-dependent serine
endoprotease that can cleave precursor protein at their
paired basic amino acid processing sites. Some of its sub-
strates are transforming growth factor beta related pro-
teins, proalbumin, and von Willebrand factor. In 1998,
a study reported abnormalities of von Willebrand factor
in adults with CHD [28]. Interestingly, a protein from
the same family, proproteinconvertasesubtilisin-like/kexintype 9, which is encoded by the PCSK9 gene, is a key regu-
lator of plasma low density lipoprotein cholesterol and has
emerged as a promising target for prevention and treat-
ment of coronary heart diseases. A recent genome-wide
association study further bolstered the importance of
PCSK9 by establishing a link between a nearby SNP and
early onset myocardial infarction [29].
Conclusions
We have conducted a whole genome linkage analysis for
CHD using MOD score analysis. We used a total num-
ber of 177,568 SNPs providing a good coverage of the
genome in a sample of 6 families of Spanish origin with
members affected with anatomically distinct CHD: ASD,
VSD, TOF, TGV, and DORV. The aim of this study was
the identification of chromosomal regions that are impli-
cated in a possible common genetic framework shared
by distinct types of CHD. Two interesting linkage re-
gions were found, on chromosome 15 and 18. The
highest linkage peak was obtained at position 18q21.2
(LOD = 3.9, Pempirical = 0.0005) and the second highest
peak at 15q26.3 (LOD = 3.5, Pempirical = 0.0004) using
MOD-score analysis. In addition, at 15q26.3 a significant
association was obtained for a SNP (rs3784481, P value =
0.0025) using family-based association analysis. Imprinting
analysis of the data in the present study did not confirm
the hypothesis of a possibly imprinted locus. When
looking at these two linkage regions in detail, four genes
are located there, three very close to each other at 15q26.3
and one at 18q21.2.
As in all research work, our results have some un-
avoidable limitations. They have been obtained using
linkage techniques with a small sample size. It is well
known that large, multi-generation pedigrees are the
most informative for linkage analysis. However, such
pedigrees are difficult to find when investigating com-
plex diseases with a high and early mortality such as
CHD. That might explain why to date there have been
so few genome-wide linkage scans involving affected
families with CHD. Therefore, despite the fact that our
study comprising 6 families is small compared with link-
age studies for other disorders, it is, thus far, the largest
family study performed in CHD. Moreover, our findings
on chromosome 15 are corroborated by family-based
association analysis (with 7 additional trios). Clearly,
recruiting more families with CHD will help to verify
this linkage evidence as well as to identify new linkage
regions.
We report in this study two genetic regions linked to
CHD predisposition. There are three candidate genes lo-
cated in the 15q26.3 region very close to each other
(SELS, SNRPA1 and PCSK6) and one gene at 18q21.2
(TCF4). Only one of these genes, SELS, was previously
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other three genes reported in this study may be considered
as novel candidate loci for CHD.
While several genome scans have reported susceptibi-
lity genes for specific types of CHD, very few (only one
[17], and the one presented here) have identified suscep-
tibility genes that predispose to developing anatomically
distinct types of CHD and should form the basis of new
analyses of both linkage and association studies on
CHD. Future linkage studies may benefit in power from
larger sample size, and also case–control studies will
benefit from direction or corroboration given by linkage
scans. For example, the extensive multiple testing prob-
lem in genome-wide association studies can be partially
alleviated by a weighted Bonferroni correction or Bayesian
analysis that employs linkage data [30]. The results pre-
sented here should facilitate the discovery of both com-
mon and rare variants that confer genetic susceptibility
for CHD and help the understanding of heart mecha-
nisms. Understanding the etiology of CHD will also help
to identify possible complications and risk factors for sur-
gery or treatment, as patients (babies and children) with
genetic syndromes or extracardiac anomalies are generally
at higher risk of operative mortality and morbidity.Figure 2 Pedigree structures. Pedigree structures used to perform linkag
affected with CHD - DORV, VSD, TOF, TGV, or ASD – were used in family-baMethods
Subjects
A total number of 6 families comprising 48 individuals
(19 females, 29 males) and 7 trios (an affected proband
and both parents) of Spanish origin were recruited at the
University Hospital Son Espases (HUSE) of the Balearic
Islands and at the Puerta del Hierro University Hospital in
Madrid. Pedigree structures are illustrated in Figure 2.
The inclusion criterion for all patients was a CHD present
at birth. Patients and their families were asked to partici-
pate in the study within the clinical practice and blood
samples were taken. All members included in the study
were checked for the presence of deletions or duplications
using the same SNP-array analysis. Individuals that were
found to carry a suggestive or clearly causative deletion or
duplication (22q11.2 or other) were excluded from the
analysis. All participants provided their written informed
consent to participate in the study. A statement of in-
formed consent form was signed by the parents of all par-
ticipating children under 18 years old, following protocols
approved by the ethical committee for clinical research of
the Balearic Islands (IB 963/08; Comité ético de inves-
tigación clínica de las Islas Baleares; CEIC). The study
conformed to all ethical guidelines of the institutionse analysis. In addition, 7 trios (an affected proband and both parents)
sed association analysis.
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low the guidelines included in the June 1964 Declaration
of Helsinki (entitled “Ethical Principles for Medical
Research Involving Human Subjects”). All sample identi-
fiers were re-encoded in a way that only the clinicians are
able to access personal information.
DNA isolation and genotyping
All patients had a single tube of blood drawn at the time of
enrollment, which was collected centrally for subsequent
DNA extraction. Genotyping reactions of 52 individuals
were performed at the Spanish genotyping center (CeGen)
facilities in Barcelona using the Illumina (California, USA)
Human660W-Quad chip, following the manufacturer’s
instructions.
Data quality control
Because genotyping errors can lead to incorrect infer-
ences about gene flow in pedigrees and may reduce the
effectiveness of linkage analysis, strict quality controls
(QC) were performed in our data. First of all, the soft-
ware Graphical Representation of Relationship Errors
(GRR) was used to identify errors in the structure of the
pedigrees and to eliminate duplicate samples, monozy-
gotic twins, and unrelated subjects [31]. In one family
GRR detected an inconsistency involving a mother and
her two children. Eventually it turned out that the chil-
dren’s genotypes were mutually consistent and only the
mother’s genotypes were removed from the analysis. All
individuals were also tested for sex consistency. After-
wards, the PEDCHECK software was used to detect
marker typing incompatibilities [32]. A total number of
3271 (0.6%) incompatibilities were detected and those
genotypes were removed from the data. Additional QC
was undertaken to check for unlikely double recom-
binants. Two or more close recombination events on the
same chromosome are uncommon due to the chance
distribution of chiasmata, and because of interference.
To detect such problematic genotypes the “error detec-
tion” option from the MERLIN v1.1.2 software was used
and the unlikely genotypes were subsequently removed
from the data using the “pedwipe” option [33]. Once
Mendelian inconsistencies and unlikely genotypes were
resolved, SNPs with call rates below 95%, monomorphic
SNPs, and SNPs with a missing genetic position were
also removed from the analysis. At the end, 93.95% of
the original SNPs survived the QC. Allele frequencies
were then estimated with MERLIN v1.1.2 using a
maximum-likelihood procedure.
Data preparation for linkage analysis
In linkage, when analyzing SNPs in pedigrees where some
parental genotypes are missing it is necessary to model for
marker-marker LD prior to the analysis. Ignoring such LDcan result in severe biases in linkage results [34]. That is
why pairwise LD between each pair of SNP loci was ana-
lyzed, using the procedure ldmax in the GOLD software
[35]. ldmax calculates r2 values from haplotype frequen-
cies estimated via the expectation maximization (EM)
algorithm of Excoffier and Slatkin [36]. In our data, when-
ever a pair of SNPs was in LD (r2 > 0.20), one of the two
SNPs was removed from the analysis. With the resulting
data set a genome-wide linkage analysis was performed on
a total number of 6 pedigrees with sizes varying from 4 to
13 members. After QC, a total number of 177,568 SNPs
was analyzed, with 174,475 from the autosomes, 3078
from the X-chromosome, and 15 SNPs from the pseu-
doautosomal regions (PAR1 and PAR2).
Statistical methods
In parametric linkage analysis (LOD scores) the trait-
model parameters, i.e., the penetrances and disease allele
frequency, must be specified prior to the analysis. It is
well known that the power to detect linkage decreases
when the specified model is not sufficiently close to the
true one. Consequently, we calculated multipoint MOD
scores, i.e., LOD scores that were maximized over trait-model
parameters using the program GENEHUNTER-MODSCORE
(GH-MOD v3.0) [37]. This program calculates MOD
scores automatically by varying the disease-allele frequency
and three penetrances. We used the option “modcalc
single” to perform a separate maximization for each ge-
netic position assumed for the putative disease locus. This
procedure yields a MOD score in conjunction with the
penetrances and disease allele frequency of the best-fitting
trait model for every genetic position. MOD score analysis
represents a comprehensive way to analyze linkage data
when the mode of inheritance is unknown; in general this
procedure is particularly well suited for the genetic dissec-
tion of a complex trait [38].
It has also been observed that the CHD risk for chil-
dren of mothers with a CHD is consistently higher than
for those of fathers with a CHD [39,40]. One possible
explanation for the increased transmission through
females is a paternal imprinting mode of inheritance,
i.e., offspring will be affected only if the inherited disease
allele comes from the mother. Hence, we also checked
for a parent-of-origin effect using two different pene-
trances for heterozygous individuals to take the parent
who transmitted the disease allele into account (see “im-
printing” option of GH-MOD v3.0).
A MOD-score analysis leads to an inflation of the type
I error when compared to LOD scores calculated under
a single parametric model. Therefore, in the context of
MOD-score analysis, significance criteria for LOD scores
cannot be applied without correction. To assess signifi-
cance for a MOD score empirical P values need to be
calculated. We used 5000 replicates, each one generated
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the assumption of no linkage and Hardy-Weinberg equi-
librium, using the same pedigree structure, affection sta-
tus, marker spacing, and allele frequencies as in the real
data set. Replicates were analyzed like the original data.
The empirical P value was obtained as the proportion of
replicates showing a MOD score equal to or higher than
the one observed in the real data set.
We computed MOD and MOD-imprinting for all
autosomes. The MOD score has not been implemented
so far for the X-chromosome. Therefore, we performed
LOD-score analysis assuming different genetic models
for the X-chromosome, ranging from completely dom-
inant to completely recessive modes of inheritance. In
addition, the PAR1 and PAR2 were also investigated.
Genetic markers in the PARs follow the same inheri-
tance pattern as autosomal markers, becoming pro-
gressively more sex-linked (i.e., recombination events
are becoming rarer between X and Y) as they ap-
proach the pseudoautosomal boundary. When using
multipoint linkage analysis in the PARs, it is crucial to
use sex-specific maps since there exists a marked dif-
ference in recombination frequencies between males
and females [41]. We used pseudoautosomal sex-
specific genetic coordinates [41] implemented in the
Rutgers map [42]. The sex-specific genetic positions were
interpolated using a local regression with a quadratic fit as
implemented by the “locfit” package [43] of the statistical
software R. In order to obtain a mapping that is monoton-
ous in the base pair positions we used R’s “monoProc”
package which monotonizes the local regression fit [44].
Finally, only in those regions where the most signifi-
cant linkage signals were obtained, to corroborate and
narrow the significant regions, family-based association
analysis together with the trio families was performed
using the LAMP software [45]. LAMP uses a maximum
likelihood model to extract the exact information on
genetic linkage and association from samples of unre-
lated individuals, sib pairs, trios, and larger pedigrees.
P values obtained by the family-based association ana-
lysis were adjusted using Bonferroni correction (using
the total number of SNPs in each specific region of link-
age) to account for multiple testing. We used an overall
type I error rate of 0.05.
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